Literature DB >> 27732770

Thromboelastographic monitoring of the effect of unfractionated heparin in healthy dogs.

Christopher M McLaughlin1, Steven L Marks1, David C Dorman1, Alison Motsinger-Reif2, Rita M Hanel1.   

Abstract

OBJECTIVE: To characterize the correlation between thromboelastography (TEG) variables using strong activators and anti-Xa (AXa) activity in healthy dogs administered subcutaneous unfractionated heparin (UFH).
DESIGN: Prospective experimental study.
SETTING: University research facility. ANIMALS: Eight adult random-source male dogs. INTERVENTION: Dogs were randomized to receive subcutaneous UFH at 200, 250, or 300 IU/kg every 8 hours for a total of 10 injections. Blood samples were collected at time 0 (preheparin) and 3, 6, and 8 hours after the 1st (Day 1) and 10th (Day 4) UFH injection.  After the 8-hour blood sample was obtained on day 4, a 100 IU/kg IV bolus of UFH was administered and an additional blood sample was collected 1 hour later (hour 9). AXa activity, activated partial thromboplastin time (aPTT), and TEG (with up to 5 activators) were performed at each time point.  Modes of activation for TEG included  recalcified (Ca), Ca with heparinase (CaH), CaH and tissue factor 1:3600 (CTF3600H), Ca with tissue factor 1:100 (CTF100), and RapidTEG. Spearman rank correlations were calculated for each of the aforementioned parameters and the AXa activity. P-values were corrected for multiple comparisons with a Bonferroni correction.
MEASUREMENTS AND MAIN RESULTS: Significant correlations were found between AXa activity and the TEG R values generated with CTF100 (R = 0.83, P ≤ 0.0001) and RapidTEG (R = 0.90, P < 0.0001), as well as both forms of aPTT measurement (R = 0.86 and 0.84, P < 0.0001).
CONCLUSIONS: This study demonstrates that TEG variables derived using robust activation correlate with AXa activity as well as aPTT and have the potential to be used for monitoring UFH therapy in healthy dogs.  Future studies are warranted to evaluate its diagnostic utility in critically ill animals. © Veterinary Emergency and Critical Care Society 2016.

Entities:  

Keywords:  RapidTEG; anti-Xa; anticoagulation monitoring; canine; thrombosis

Mesh:

Substances:

Year:  2016        PMID: 27732770     DOI: 10.1111/vec.12526

Source DB:  PubMed          Journal:  J Vet Emerg Crit Care (San Antonio)        ISSN: 1476-4431


  4 in total

1.  Comparison of assessment of coagulation in healthy dogs by the TEG 6s and TEG 5000 viscoelastic analyzers.

Authors:  Lance R Wheeler; Thomas H Edwards; Justin A Heinz; Laura L F Scott; Lonnie E Grantham; Jeffrey D Keesee; Alice F Henderson; Angelina C Gerardo; Guillaume Hoareau; James A Bynum
Journal:  J Vet Diagn Invest       Date:  2022-07-19       Impact factor: 1.569

2.  ACVIM consensus statement on the treatment of immune-mediated hemolytic anemia in dogs.

Authors:  James W Swann; Oliver A Garden; Claire L Fellman; Barbara Glanemann; Robert Goggs; Dana N LeVine; Andrew J Mackin; Nathaniel T Whitley
Journal:  J Vet Intern Med       Date:  2019-03-07       Impact factor: 3.333

3.  Therapeutic monitoring of rivaroxaban in dogs using thromboelastography and prothrombin time.

Authors:  Junwoo Bae; Hyunwoo Kim; Woosun Kim; Suhee Kim; Jinho Park; Dong-In Jung; Dohyeon Yu
Journal:  J Vet Intern Med       Date:  2019-03-11       Impact factor: 3.333

4.  Thromboelastography-based anticoagulation management during extracorporeal membrane oxygenation: a safety and feasibility pilot study.

Authors:  Mauro Panigada; Giacomo E Iapichino; Matteo Brioni; Giovanna Panarello; Alessandro Protti; Giacomo Grasselli; Giovanna Occhipinti; Cristina Novembrino; Dario Consonni; Antonio Arcadipane; Luciano Gattinoni; Antonio Pesenti
Journal:  Ann Intensive Care       Date:  2018-01-16       Impact factor: 6.925

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.